US stock · Healthcare sector · Biotechnology

BeiGene, Ltd.

BGNE

NASDAQ

216.04

USD

-1.02

(-0.47%)

Market Closed

-11.70P/E

-23Forward P/E

-0.48P/E to S&P500

22.623BMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

8 Aug-14 Aug

Shares Short

5/31/23

1.84M

Short % of Float

- -

Short % of Shares Outs.

1.76%

% Held by Insiders

19.84%

% Held by Institutions

52.49%

Beta

0.79

PEG Ratio

0.12

52w. high/low

280.62/124.46

Avg. Daily Volume

0.19M

Return %

Stock

S&P 500

1 year

37.58

5.55

3 years

25.78

33.85

5 years

0.36

54.93

Scale: |

High

Low

- -

37.89

22.51

118.95

29.58

220.10

95.34

210.35

108.00

322.98

118.55

426.56

222.21

275.72

118.18

280.62

208.85

Currency: USD

- -

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

- -

0.12

0.78

0.28

0.03

5.23

3.58

7.13

3.70

14.09

16.96

0.00

Earnings per share

- -

(0.08)

(1.10)

(1.81)

(3.00)

(2.04)

(12.15)

(15.80)

(19.13)

(16.93)

(24.01)

(15.24)

FCF per share

- -

0.04

(0.56)

(1.43)

(2.85)

(1.01)

(12.42)

(15.13)

(18.12)

(15.56)

(17.93)

(0.01)

Dividends per share

- -

CAPEX per share

- -

0.00

0.04

0.17

0.59

1.29

2.54

2.64

2.74

- -

0.00

Book Value per sh.

- -

(0.42)

1.55

2.36

8.89

14.71

31.37

16.02

46.35

74.79

- -

0.01

Comm.Shares outs.

- -

338,619

Avg. annual P/E ratio

- -

(9.9)

(29.5)

(12.9)

(8.9)

(10.8)

(19.5)

(7.6)

(11.7)

P/E to S&P500

- -

(0.4)

(1.3)

(0.5)

(0.4)

(0.3)

(0.7)

(0.4)

(0.5)

Avg. annual div. yield

- -

Revenue (m)

- -

238

198

428

309

1,176

1,416

1,557

Operating margin

- -

(49.0)%

(120.9)%

(643.7)%

(10,940.2)%

(41.3)%

(356.1)%

(224.2)%

(536.7)%

(122.3)%

(126.4)%

(112.0)%

Depreciation (m)

- -

Net profit (m)

- -

(7)

(18)

(57)

(119)

(93)

(674)

(949)

(1,597)

(1,413)

(2,004)

(1,923)

Income tax rate

- -

(0.0)%

(2.5)%

2.3%

(0.7)%

1.1%

1.8%

(2.2)%

(2.6)%

Net profit margin

- -

(67.2)%

(140.2)%

(647.7)%

(11,141.8)%

(39.1)%

(339.9)%

(221.5)%

(517.0)%

(120.2)%

(141.5)%

(126.5)%

Working capital (m)

- -

(27)

339

764

1,697

862

3,885

- -

(0)

3,450

Long-term debt (m)

- -

155

190

241

184

- -

239

Equity (m)

- -

(39)

353

670

1,739

962

3,869

6,243

- -

4,157

ROIC

- -

21.8%

(36.6)%

(68.5)%

(32.2)%

(10.6)%

(33.9)%

(73.8)%

(35.3)%

(16.3)%

(21,668,780.0)%

(37.5)%

Return on capital

- -

(36.8)%

(27.5)%

(47.9)%

(29.4)%

(8.8)%

(30.8)%

(59.0)%

(28.8)%

(16.6)%

(3,976,160.4)%

(28.8)%

Return on equity

- -

19.4%

(70.9)%

(76.8)%

(33.8)%

(13.9)%

(38.7)%

(98.6)%

(41.3)%

(22.6)%

(Infinity)%

(46.3)%

Plowback ratio

- -

100.0%

- -

100.0%

Div.&Repurch./FCF

- -

Capital Structure

4 May · 2023 | Q1

All numbers in millions

Total liabilities

$ 1,799

Total assets

$ 5,957

Long-term debt

$ 239

Cash and equiv.

$ 3,539

Goodwill

$ - -

Retained earnings

$ (7,429)

Common stock

1,354,165

Enterprise Value

$ 19,323

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

4,651

Receivables

- -

Inventory

- -

Other

141

(1,382)

Current assets

4,961

- -

Acc. Payable

232

262

- -

Debt due

349

- -

Other

494

(262)

Current liabilities

1,075

- -

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

20.37%

97.34%

2,494.26%

Cash flow

15.24%

24.88%

180.64%

Earnings

41.78%

34.85%

134.03%

Dividends

- -

Book value

- -

Insider Trading

Type

Date

Wang Lai

Sale

06/07/23

Wang Lai

Sale

161

06/07/23

Wang Lai

Sale

111

06/07/23

Wang Lai

Sale

116

06/07/23

Wu Xiaobin

Sale

531

06/07/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

606

150

206

214

1,176

2022

307

342

388

380

1,416

2023

448

- -

Earnings per share

Currency: USD

Year

Total

2021

0.80

(5.75)

(4.96)

(7.02)

(16.93)

2022

(5.20)

(6.85)

(6.68)

(5.34)

(24.06)

2023

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

- -

2022

- -

2023

- -

Company Description

Sector:

Healthcare

Industry:

Biotechnology

CEO:

Mr. John V. Oyler

Full-time employees:

9,400

City:

Cambridge

Address:

55 Cambridge Parkway

IPO:

Feb 3, 2016

CIK:

0001651308

Website:

beigene.com

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Powered by AI

BeiGene, Ltd.

216.04